Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001904552 | SCV002119886 | uncertain significance | Combined oxidative phosphorylation defect type 17 | 2022-07-13 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 622 of the ELAC2 protein (p.Glu622Gly). This variant is present in population databases (rs119484087, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with ELAC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1359788). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002489990 | SCV002780716 | uncertain significance | Prostate cancer, hereditary, 2; Combined oxidative phosphorylation defect type 17 | 2022-04-13 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV004693811 | SCV005192736 | uncertain significance | not provided | criteria provided, single submitter | not provided |